American Cryostem (American Cryostem) LT-Debt-to-Total-Asset : 0.14 (As of Jun. 2022)

View and export this data going back to 2010. Start your Free Trial

What is American Cryostem LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. American Cryostem's long-term debt to total assests ratio for the quarter that ended in Jun. 2022 was 0.14.

American Cryostem's long-term debt to total assets ratio declined from Jun. 2021 (0.16) to Jun. 2022 (0.14). It may suggest that American Cryostem is progressively becoming less dependent on debt to grow their business.

American Cryostem LT-Debt-to-Total-Asset Historical Data

The historical data trend for American Cryostem's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

American Cryostem LT-Debt-to-Total-Asset Chart

American Cryostem Annual Data

Trend

Sep12

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.11

0.15

0.26

0.07

0.28

American Cryostem Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.16	0.28	0.12	0.15	0.14

American Cryostem LT-Debt-to-Total-Asset Calculation

American Cryostem's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Sep. 2021 is calculated as

LT Debt to Total Assets (A: Sep. 2021 )	=	Long-Term Debt & Capital Lease Obligation (A: Sep. 2021 )	/	Total Assets (A: Sep. 2021 )
	=	0.293	/	1.056
	=	0.28

American Cryostem's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2022 is calculated as

LT Debt to Total Assets (Q: Jun. 2022 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2022 )	/	Total Assets (Q: Jun. 2022 )
	=	0.151	/	1.058
	=	0.14

American Cryostem (OTCPK:CRYO) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

American Cryostem LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of American Cryostem's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

American Cryostem (American Cryostem) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » American Cryostem Corp (OTCPK:CRYO) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Meridian Road, Suite 5, Eatontown, NJ, USA, 07724

Website

http://www.americancryostem.com

American Cryostem Corp is a biotechnology company which standardizes adipose tissue-derived technologies (Adult Stem Cells) for the fields of Regenerative and Personalized Medicine. The company acts as an innovator of adipose tissue and stem cell platform technologies. It provides the clinical grade, adipose tissue and adult stem cell collection, processing, and cryo-preservation technology, providing first-in-class cellular therapy products and services for patients, physicians and researchers based on the transformative science of Regenerative and Personalized Medicine.

Executives

John S Arnone	director, officer: Chairman	111 GREAT NECK RD, GREAT NECK NY 11021
Anthony Francis Dudzinski	director, officer: COO	188 EAST BERGEN PLACE, SUITE 204, RED BANK NJ 07701
Acs Global, Inc.	10 percent owner	188 E. BERGEN PLACE, SUITE 204, RED BANK NJ 07701
Christopher Joseph Neill	10 percent owner	188 EAST BERGEN PLACE, SUITE 204, RED BANK NJ 07701
Hector Medina	director, 10 percent owner, officer: President and Director	1206 STAGECOACH TRAIL LOOP, CHULA VISTA CA 91915